Competing interests
FT reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Silvio Grasso Consulting (institutional), SAKK (institutional), Merck (institutional), Novartis (istitutional), Bayer (individual) and MSD (individual); support for attending meetings or travel from Bayer (individual); and participation on a data safety monitoring board or advisory board for Bayer (individual) and Telix (individual). SG (last 2 years) personal honoraria for invited speaker for Schweizerische Gesellschaft für Medizinische Onkologie (SGMO)/Meister ConCept GmbH; other honoraria from University of Applied Sciences and Arts of Southern Switzerland (SUPSI). Travel grants from Bayer, Gilead, Intellisphere LLC, Johnson & Johnson. Institutional honoraria advisory boards or in Independent Data Monitoring-/Steering Committees from Amgen, Astellas, AstraZeneca, Avalere Health, Bayer, Bristol-Myers Squibb, GSK, Ipsen, LinkinVax, Macrogenics, Merck, MDS Merck Sharp & Dohme, Novartis, Pfizer; invited speaker for Emirates Oncology, EPG Health, ESMO, Intellisphere LLC, Medtoday Switzerland, Orikata, PeerVoice, Pfizer, Schweizerische Gesellschaft für Medizinische Onkologie (SGMO)/Meister ConCept GmbH, Silvio Grasso Consulting, Swiss group for Clinical Cancer Research (SAKK)/Swiss Cancer Institute (SCI), SwissInfoMed, Symposia Congressi, UroPratica Group. Patent for a research method for biomarker WO2009138392. KF reports honoraria for lectures from AstraZeneca, Bayer, Ono, Eisai, MSD, Bristol-Myers Squibb, Takeda, Merk, Astellas, Janssen, and Novartis. HS reports research funding from Astellas, AstraZeneca, Bayer, Chugai, Eli-lily, Janssen, MSD, Nihon Kayaku, and Sanofi; advisory fees from Astra Zeneca, Bayer, Chugai-Roche, Eli Lilly, Ferring, Janssen, MSD, Novartis, Pfizer, and Sanofi; and lecture fees from Astellas, AstraZeneca, Bayer, Janssen, Novartis, Pfizer, and Sanofi. CNS reports Consulting fees: Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Gilead; Merck; MSD; Pfizer; Janssen; Roche; Medscape; UroToday; Tolmar; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Merck; Pfizer GP reports financial Interests: ACCORD Healthcare Italia Srl, Steeering Committee, Personal, consultant fees; Astellas, Advisory Board, Personal, consultant fees; Astrazeneca, Advisory Board, Personal, consultant fees; Amgen, Advisory Board, Personal, consultant fees; Boehringer, Advisory Board, Personal, consultant fees; Bayer, Advisory Board, Personal, consultant fees; Brystol Myers Squibb, Advisory Board, Personal, consultant fees; Ipsen, Advisory Board, Personal, consultant fees; Janssen, Advisory Board, Personal, consultant fees; Eisai, Advisory Board, Personal, consultant fees; Janssen Cilag, Advisory Board, Personal, consultant fees; Merck Sharp & Dohmes, Advisory Board, Personal, consultant fees; Merck, Advisory Board, Personal, consultant fees; Pfizer, Advisory Board, Personal, consultant fees; Roche, Advisory Board, Personal, consultant fees; Eli Lilly, Advisory Board, Personal, consultant fees; Menarini Group, Other, Personal, workgroup; Telix Pharmaceuticals Limited, Advisory Board, Personal, consultant fees; GE Medical Systems Italia SPA, Other, Personal, consultant fees; Ipsen, Research Grant, Institutional, research funding for no profit clinical trial Coordinating PI; Gilead, Research Grant, Institutional, research funding for no profit clinical trial; MSD, Research Grant, Institutional, research funding for no profit clinical trial; Janssen, Research Grant, Institutional, research funding for no profit clinical trial; Board of Directors : ASCO Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer living guideline 2025 MS reports travel support from 2022 Janssen; 2023: Novartis; 2024: Astellas, Ipsen; 2025: Bayer, Novartis DES reports personal Fees: AstraZeneca, Bayer, Boston Scientific, Janssen, Novartis, Pfizer PCB reports grants or personal fees from Astellas; AstraZeneca; Bayer, Eisai; Ipsen; Caris Life Sciences; Exelixis; Janssen, Pfizer, Sanofi, Seattle Genetics, BMS, Bayer, Guardant Health; Caris Life Sciences; Myovant; Medscape; UroToday; MJH Life Sciences CM received fee as speaker in symposia organized by J&j, Astellas, msd, Orion Pharma JDCL reports sonsultant advisory Role: Astrazeneca, BMS; speaking: Astrazneca, BMS, Leopharma, Rovi MCN reports research travel from Pfizer and Ipsen, consulting fees (institutional) from BMS, Bayer, Ipsen and Merck. LGH reports grants or contracts from any entity: astellas (institutional), Bayer (institutional); Consulting fees: Astellas (institutional), Bayer (institutional), Janssen (institutional); Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Astellas (institutional), Bayer (institutional), Janssen (institutional), Amgen (institutional); support for attending meetings and/or travel: Bayer (institutional); patents planned, issued or pending: Australian Patent Application No. 2022902527 International (PCT) Patent Application No. PCT/AU2023/050849 Pending (institutional); Leadership or fiduciary role in other board, society, committee or advocacy group: ANZUP Board (unpaid) RM reports consulting fees: Bayer (individual); Support for attending meetings and/or travel (individual) RC reports advisory role (institutional): MSD, Astra Zeneca, BMS, Merck, Roche, Bayer, Astellas, Janssen, Pfizer, Ipsen, Debiopharm, Accord, Novartis, Sandoz; Speaker role (institutional): Astellas, Janssen, Merck, Ipsen, Accord; Travel support (institutional): Ipsen, Astra Zeneca GLB reports personal fees from advisory boards (Accord, AstraZeneca, Amgen, Merck) and speaker bureaus (Astellas, AstraZeneca, Amgen, Bayer, Merck, Pfizer). Travel/accommodation for scientific conferences: Accord, Merck, Janssen VC has served as a consultant/advisory board member for Johnson&Johnson, Astellas, Merck, AstraZeneca, Amgen, EISAI, Recordati, Novartis, Ipsen, and Bayer and has received speaker honoraria or travel support from Astellas, Johnson&Johnson, Ipsen, Bayer, Gilead, Novartis, GSK and BristolMyers Squibb. HML reports employment with the Garvan Institute of Medical Research, and is a co-inventor of a patent for a prognostic biomarker in prostate cancer (PCT/AU2023/050849). The other authors declared no conflicts of interest.
